OTCMKTS:IMMVF Immunovia AB (publ) (IMMVF) Stock Price, News & Analysis → Musk’s new company could top a trillion? (From Paradigm Press) (Ad) Free IMMVF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.15▼$0.1550-Day Range N/A52-Week Range$0.84▼$2.00VolumeN/AAverage Volume12,942 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisShort InterestStock AnalysisShort Interest Get Immunovia AB (publ) alerts: Email Address Ad The Freeport SocietyBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________. About Immunovia AB (publ) Stock (OTCMKTS:IMMVF)Immunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.Read More Ad The Freeport SocietyBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________. IMMVF Stock News HeadlinesMarch 17, 2023 | prnewswire.comImmunovia publishes prospectus relating to the rights issueDecember 5, 2022 | finance.yahoo.comImmunovia strengthens US organization to continue commercialization of its novel IMMray™ PanCan-d testNovember 30, 2022 | finance.yahoo.comCenters for Medicare & Medicaid Services finalizes its payment determination and sets a rate of $897 for Immunovia's IMMray PanCan-d testNovember 16, 2022 | finance.yahoo.comChief Executive Offier, Philipp Mathieu, buys Immunovia warrantsNovember 12, 2022 | finance.yahoo.comImmunovia announces the financial calendar for financial year 2023November 10, 2022 | finance.yahoo.comImmunovia Publishes Interim Report Jan-Sep 2022November 5, 2022 | finanznachrichten.deImmunovia AB: Invitation to Immunovia's Q3 presentationNovember 3, 2022 | finance.yahoo.comInvitation to Immunovia's Q3 presentationOctober 20, 2022 | finance.yahoo.comNomination Committee appointed for the 2023 Annual General Meeting of Immunovia AB (Publ)October 19, 2022 | finance.yahoo.comImmunovia announces executive management team changes to accelerate execution of strategic prioritiesOctober 18, 2022 | finanznachrichten.deImmunovia AB: Immunovia launches a strategic partnership with Proteomedix to leverage R&D efforts with increased focus on commercializationOctober 17, 2022 | finance.yahoo.comImmunovia launches a strategic partnership with Proteomedix to leverage R&D efforts with increased focus on commercializationSeptember 29, 2022 | investing.comAttendo International publ AB (ATTE)September 26, 2022 | finance.yahoo.comCenters for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia's IMMray PanCan-d testSeptember 9, 2022 | investing.comImmunovia publ AB (IMMNOV)August 25, 2022 | finanznachrichten.deImmunovia AB: Immunovia Publishes Interim Report Jan-June 2022August 24, 2022 | finance.yahoo.comImmunovia Publishes Interim Report Jan-June 2022August 23, 2022 | finance.yahoo.comImmunovia to present at Gilmartin Group's Emerging Growth Company ShowcaseAugust 22, 2022 | finance.yahoo.comInvitation to Immunovia's Q2 presentationAugust 11, 2022 | finance.yahoo.comImmunovia, Inc. Issued Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray™ PanCan-d testJuly 5, 2022 | finance.yahoo.comImmunovia: CPT PLA Code for the IMMray™ PanCan-d test approvedJune 30, 2022 | finance.yahoo.comThe PanDIA-1 study, for early detection of pancreatic cancer in newly onset type 2 diabetics, moves into next phaseJune 27, 2022 | finance.yahoo.comPanFAM-1 Results Partly InconclusiveJune 27, 2022 | finance.yahoo.comInvitation to Immunovia's Presentation of PanFAM-1 ResultsJune 3, 2022 | seekingalpha.comImmunovia AB appoints Philipp Mathieu as permanent CEOSee More Headlines Receive IMMVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovia AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/29/2013Today6/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:IMMVF CUSIPN/A CIKN/A Webwww.imvaccine.com Phone(902) 492-1819FaxN/AEmployees69Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Patrik DahlenChief Exec. OfficerMr. Hans Liljenborg (Age 63)Chief Financial Officer Ms. Lotta Blomgren (Age 61)Operations Director Mr. Rolf Ehrnström (Age 68)Chief Scientific Officer Ms. Laura Chirica (Age 53)Chief Commercial Officer Mr. Henrik Winther (Age 55)Sr. VP of Bus. Devel. Mr. Michael PettigrewSr. VP of Sales - North AmericaMs. Linda Dexlin Mellby (Age 42)VP of R&D Dr. Thomas C. King (Age 63)Medical Director More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors IMMVF Stock Analysis - Frequently Asked Questions How were Immunovia AB (publ)'s earnings last quarter? Immunovia AB (publ) (OTCMKTS:IMMVF) released its earnings results on Friday, November, 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. This page (OTCMKTS:IMMVF) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovia AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovia AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.